The neuroendocrine tumour (NET) unit at the Royal Free Hospital – Private Patients Unit has an international reputation for the management of neuroendocrine tumour patients. In 2010 it was the first UK centre to be awarded European Centre of Excellence. It currently receives 30-35 new referrals per month (360 – 420 per year) and has an active patient cohort of over 1,600 patients. We receive referrals from across the UK as well as from abroad, and we are the designated centre for NETs within the North London Cancer Network.
The aim of the Royal Free Hospital – Private Patients Unit neuroendocrine tumour group is to provide optimal management for patients with neuroendocrine tumours, taking into account how the tumour affects each individual.
We work within a multidisciplinary team and aim to enhance the prospects for treatment by a combination of clinical and laboratory research. The RFH PPU NET unit and oncology department conducts a number of clinical and basic science research trials relating to the treatment of and the pathogenesis of NET development.
The NET unit clinicians and researchers collaborate with clinicians and research staff in the UK and abroad. The clinical lead and head of the neuroendocrine unit is Professor Martyn Caplin.